Table 3.

SU14813 is efficacious in a bone marrow myeloproliferative disease model

TreatmentDose (mg/kg)Time to progression (d ± SE)P vs vehicle
Vehicle23.3 ± 2.6
SU1481310 BID41.6 ± 4.40.006
SU1481320 BID42.7 ± 4.20.004
  • NOTE: MV4;11 human AML cells were infused i.v. into cyclophosphamide-pretreated nonobese diabetic/severe combined immunodeficient mice. Thirty days later, p.o. administration of SU14813 at the indicated dosages and regimens was initiated. Average time to progression (as assessed by the appearance of hind limb paralysis) is indicated. Statistical analyses were done using the two-tailed Student's t test. n = 15 animals per group. —, not applicable.